Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing